Pfizer Inc. Q3 2008 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 28, 2008, and the nine-month period ended on the same date. Pfizer operates primarily in two segments: Pharmaceutical and Animal Health. The company is a global research-based enterprise focused on the discovery, development, and marketing of medicines. As of November 4, 2008, there were approximately 6.74 billion shares of voting common stock outstanding.
Key Financial Metrics
| Metric (in millions) | Q3 2008 | Q3 2007 | 9M 2008 | 9M 2007 |
|---|---|---|---|---|
| Revenues | $11,973 | $11,990 | $35,950 | $35,548 |
| Net Income | $2,278 | $761 | $7,838 | $5,420 |
| Diluted EPS | $0.34 | $0.11 | $1.16 | $0.78 |
| Operating Cash Flow (9M) | $12,265 | $9,586 | ||
| Cost of Sales Margin | 17.7% | 38.5% | 17.8% | 24.2% |
| Total Debt | $16,345 | $13,139 | N/A | |
| Working Capital | $26,724 | $25,014 |
Note: Q3 2007 results were significantly impacted by a $2.8 billion pre-tax charge related to the exit of the Exubera product line.
Material Changes vs. Prior Period
- Profitability Surge: Net income increased 199% in Q3 2008 compared to Q3 2007. This is largely attributable to the absence of the $2.8 billion Exubera exit charge recorded in Q3 2007, lower restructuring costs, and favorable foreign exchange impacts.
- Revenue Stability: Revenues remained flat in Q3 2008 ($11.97B vs $11.99B) and grew 1% for the nine-month period. Growth was driven by new products (Lyrica, Sutent) and international markets, offset by patent expirations (Zyrtec, Camptosar, Norvasc) and a $217 million revenue reduction due to an adjustment of prior years' product return liabilities.
- Litigation Charges: In Q3 2008, Pfizer recorded approximately $900 million in litigation-related charges (pre-tax) to resolve U.S. consumer fraud class actions and personal injury claims involving Celebrex and Bextra.
- Acquisitions: The company recorded $567 million in acquisition-related in-process research and development (IPR&D) charges for the nine months ended Sept 28, 2008, related to acquisitions of Encysive, Serenex, CovX, and Coley Pharmaceutical Group.
Guidance, Outlook, and Risks
Revised 2008 Guidance (Announced Oct 21, 2008):
- Revenues: Narrowed to $48.0 billion – $49.0 billion (previously $47.0B – $49.0B).
- Adjusted Diluted EPS: $2.36 – $2.41 (previously $2.35 – $2.45).
- Reported Diluted EPS: Lowered to $1.61 – $1.71 (previously $1.73 – $1.88).
Management Commentary: Management expects to achieve a net reduction of the pre-tax total expense component of Adjusted income of at least $2.0 billion by year-end 2008 compared to 2006 levels. The company maintains a strong liquidity position with $18.95 billion in net financial assets.
Risks and Contingencies:
- Patent Expirations: Continued revenue pressure from generic competition for Lipitor, Norvasc, and Camptosar.
- Legal Proceedings: Ongoing investigations by the Department of Justice regarding COX-2 medicines (Bextra/Celebrex) and patent challenges for Lipitor and Norvasc.
- Product Safety: Labeling changes for Chantix regarding suicidal thoughts have negatively impacted U.S. sales trends.
- Market Conditions: Volatility in global financial markets, though management states this has not significantly impacted liquidity.
Investor Verification Checklist
- Litigation Resolution: Verify the final court approval of the $900 million Celebrex/Bextra settlement and potential for additional unknown claims.
- Product Return Adjustment: Confirm the long-term impact of the $217 million revenue reduction related to the revised methodology for product return liabilities.
- Patent Defense: Monitor the outcome of patent challenges for Lipitor (Apotex) and Norvasc (Pharmascience/Dr. Reddy's) in the U.S. and Canada.
- Chantix Performance: Track the effectiveness of the relaunched marketing campaign and the impact of FDA label warnings on prescription trends.
- Cost-Reduction Targets: Validate the achievement of the $2.0 billion pre-tax expense reduction target by year-end 2008.